anti-GBM disease

anti-GBM disease

a rare autoimmune disease; kidney or pulmonary disorder in which the glomerular basement membrane is damaged by an antigen-antibody reaction. The kidney itself may serve as the antigenic target in the reaction. Also called Goodpasture's disease.
References in periodicals archive ?
In this setting, patients have a worse prognosis than ANCA isolated conditions, with a clinical course more similar to pure anti-GBM disease.
Anti-GBM disease has similar features on light microscopy, with the addition of positive linear basement membrane staining with IgG in the glomeruli.
Anti-GBM disease is a diagnosis that is made when there is a presence of circulating anti-GBM antibodies in the serum.
Seronegative anti-GBM disease has been previously described and mostly blamed for the relative insensitivity of earlier serologic assays.
Here we present a case of seronegative anti-GBM disease with a positive p-ANCA serology.
The spectrum of glomerular diseases in this study is consistent with the global trend except for IgA nephropathy, vasculitis, and anti-GBM disease.
Subsequent chapters deal with specific renal diseases such as Anti-GBM disease, membranous nephropathy, lupus nephritis, IgArelated glomerulonephropathies, mesangiocapillary glomerulonephritis, minimal change nephropathy and focal segmental glomerulosclerosis, systemic vasculitis and crescentic glomerulonephritis, tubulointersitial nephritis, other renal disease of immunological interest and therapeutic aspects.
The other pathologic entities that can lead to crescentic GN are anti-GBM disease and immune complex-mediated GNs that have been discussed previously (see above).
In Donaghy and Rees' (1983) study, 84% of the 47 patients with anti-GBM disease had lung hemorrhage.
There were no cases of anti-GBM disease reported during the study period with one case of glomerulonephritis during the follow-up period as has been previously reported.
Patient monitoring for thyroid disorders, ITP, and anti-GBM disease is incorporated into all Genzyme-sponsored trials of alemtuzumab for the investigational treatment of MS.
Patient monitoring for ITP, thyroid disorders and anti-GBM disease is incorporated into all Genzyme-sponsored trials of alemtuzumab for the treatment of MS.